What You Should Know:
– Heartbeat Health, a healthcare technology company working to deliver effective, efficient, and engaging heart care, announced that it has partnered with Withings, as they launch their ECG-enabled hybrid ScanWatch in the U.S. on November 9.
– The Withings and Heartbeat integration is a game-changing development in the cardiovascular space – as Atrial Fibrillation, a form of irregular heart rhythm, is significantly underdiagnosed and, in some cases, can be an indicator of other underlying related cardiovascular issues.
FDA-Clearance
Withings, an early pioneer of the connected health revolution, known for bringing elegantly designed, health and wellness devices into the homes of consumers, recently received FDA clearance for its new hybrid smartwatch, ScanWatch – which has SpO2 (blood oxygenation) sensors and a built-in ECG (electrocardiogram) – capable of detecting Atrial Fibrillation.
How It Works
To take an ECG, users simply rest their finger on the ScanWatch bezel and the measurement is completed within 30 seconds. Using the Withings Health Mate app combined with Heartbeat’s seamless technology integration, the ECG is then pinged real-time to Heartbeat Health’s virtual cardiology team for clinical interpretation. The result? Individuals can quickly become more informed and understand their heart health better — and share that information with their doctors.
“Withings’ approach to their ScanWatch is groundbreaking,” says Dr. Jeff Wessler, a cardiologist and Heartbeat Health’s co-founder and CEO. “We are thrilled to be the clinical partner to help Withings users understand their heart health better — quicker than has ever previously been possible.”
